The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose expansion results.
 
Benedito A. Carneiro
Consulting or Advisory Role - Eisai; Seagen; Tempus
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Dragonfly Therapeutics (Inst); MiNK Therapeutics (Inst); Pfizer (Inst); Repare Therapeutics (Inst)
 
Ruth Perets
Honoraria - MSD
Consulting or Advisory Role - 1E Therapeutics; GalMed Pharmacueticals; Gilboa Therapeutics; MSD
Travel, Accommodations, Expenses - MSD
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Bayer; Ipsen; Jazz Pharmaceuticals; Millenium Pharamceuticals; Seagen
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Incuron (Inst); Ipsen (Inst); Lilly O. (Inst); Millenium Pharamceuticals (Inst); Mirati Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst); United Therapeutics (Inst); Vertex (Inst)
 
Patricia LoRusso
Stock and Other Ownership Interests - BAKX Therapeutics
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; BAKX Therapeutics; Bayer; Black Diamond Therapeutics; Compass Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImCheck therapeutics; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Mekanistic Therapeutics; Molecular Templates; Molecular Templates; Neurotrials Research; Pfizer; QED Therapeutics; Qualigen Therapeutics; Relay Therapeutics; Roche/Genentech; Roivant; Salarius Pharmaceuticals; Scenic Biotech; Seagen; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Stemline Therapeutics; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Lei He
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
Patents, Royalties, Other Intellectual Property - 1. Genomic signature predicting veliparib sensitivity in lung cancer patients (U.S. Application No. 62/524,711) 2. Tubulin mutations predict response to Depatuxizumab Mafodotin in patients with Glioblastoma (U.S. Application No. 16/195,384)
Travel, Accommodations, Expenses - Abbvie
 
Wijith Munasinghe
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Behnam Noorani
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Eric Feral Johnson
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Jon Zugazagoitia
Honoraria - AstraZeneca Spain; Bristol-Myers Squibb/Celgene; Guardant Health; NanoString Technologies; Pfizer; Roche/Genentech; Sanofi/Regeneron
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Guardant Health; Novartis; Novartis; Pfizer; Sanofi/Regeneron
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; Guardant Health; MSD Oncology; NanoString Technologies; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Roche/Genentech